AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

We might only be halfway through 2019, but In Vivo is taking in the long view and exploring some of the market-altering new drugs on the horizon that are expected to win approval and experience first launches at the opening of the next decade.

Boston Scientific has acquired the remaining shares of privately held mitral-valve repair device company Millipede for $325m.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.